Athira Pharma, Inc. — Form 10-Q Summary
Filing identity: The request metadata names Leonabio, Inc., but the supplied filing is for Athira Pharma, Inc. (Nasdaq: ATHA). This summary reflects the filing. Reporting period ended June 30, 2021; filed August 16, 2021. Unaudited interim financial statements.
Business context
Athira is a clinical-stage biopharmaceutical company developing small molecules intended to restore neuronal health. Its lead candidate, ATH-1017, is being studied for mild-to-moderate Alzheimer’s disease (AD). The company had no approved products and reported no product-sales revenue.
Financial results and liquidity
| Metric | Three months ended June 30, 2021 | Three months ended June 30, 2020 | Six months ended June 30, 2021 | Six months ended June 30, 2020 |
|---|---|---|---|---|
| Research and development expense | $12.0 million | $1.7 million | $19.5 million | $2.3 million |
| General and administrative expense | $4.6 million | $0.6 million | $7.9 million | $1.3 million |
| Total operating expenses | $16.6 million | $2.3 million | $27.4 million | $3.5 million |
| Grant income | $2.6 million | — | $4.4 million | Less than $0.1 million |
| Net loss | $14.0 million | $2.0 million | $22.8 million | $3.8 million |
| Basic and diluted net loss per share | $0.38 | $0.48 | $0.68 | $0.96 |
Grant income primarily reflected qualifying expenses under a National Institutes of Health (NIH) grant supporting the ATH-1017 ACT-AD Phase 2 trial. No product revenue or gross margin was reported; conventional sales margins are therefore not applicable.
For the six months ended June 30, 2021, operating cash use was $14.6 million, investing cash use was $11.3 million, and financing provided $97.0 million. Financing primarily reflected the January/February follow-on offering. Cash and cash equivalents increased by $71.1 million to $131.7 million.
At June 30, 2021, cash, cash equivalents, and investments totaled approximately $349.9 million, versus $268.2 million at December 31, 2020. Total assets were $360.1 million; total liabilities were $9.4 million, including $2.0 million of operating lease liabilities. The balance sheet reports no borrowings at period end; convertible notes had converted to preferred stock in 2020. Stockholders’ equity was $350.7 million and accumulated deficit was $63.9 million.
Material changes versus the prior comparable period
- Second-quarter operating expenses increased $14.4 million year over year. ATH-1017 trial activity, clinical drug supply, and trial-extension start-up were major drivers of higher R&D spending.
- For the first half, R&D expense increased $17.2 million and G&A expense increased $6.7 million year over year. G&A growth included higher personnel, insurance, legal, and facilities costs.
- First-half net loss rose to $22.8 million from $3.8 million, despite $4.4 million of grant income. Loss per share was lower than the prior-year period because the weighted-average share count increased substantially following the IPO and public offering.
- The company received approximately $96.8 million in net proceeds from a 2021 follow-on offering, issuing 4.6 million shares at $22.50 per share.
Outlook, commentary, risks, and unusual items
- Management estimated available cash, cash equivalents, and investments would fund operations and capital requirements through at least 2022; the filing also states sufficiency through at least 12 months following the report date. Athira expects continued significant losses and says substantial additional funding will be required over time.
- Topline results were expected by year-end 2022 for LIFT-AD, a Phase 2/3 ATH-1017 trial, and in the first half of 2022 for ACT-AD, a Phase 2 P300 trial. The filing reports COVID-19-related enrollment delays, particularly at Australian sites, and notes that open-label extensions had begun.
- ATH-1017’s earlier Phase 1a/1b study included only 11 participants with mild-to-moderate AD. The filing describes P300 latency findings as potentially informative but says a connection to improved cognition had not been established.
- On June 16, 2021, CEO Leen Kawas was placed on temporary paid leave pending an independent board committee’s review of papers co-authored during her doctoral research. COO Mark Litton assumed day-to-day CEO responsibilities. Washington State University also began a review of potential research misconduct allegations; outcomes remained unknown.
- Three securities class actions filed June 25, 2021, alleging misleading disclosures related to the research allegations, were consolidated in August. The company said it could not predict outcomes or reasonably estimate potential losses and recorded no liability.
- The filing identifies material development uncertainties, including clinical-trial efficacy and safety, patient recruitment, regulatory approval, reliance on third-party manufacturers and trial operators, competition, COVID-19 disruption, future financing needs, and intellectual-property protection. It states disclosure controls were effective and there were no material changes in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Progress, enrollment, safety, and readout timing for LIFT-AD and ACT-AD, including the significance and interpretation of clinical endpoints.
- Findings and consequences of the board committee and Washington State University reviews, including any effects on management, research, patents, grants, or university licensing relationships.
- Status, potential exposure, insurance coverage, and legal costs associated with the consolidated securities litigation.
- Cash burn and runway against management’s forecast, including expected trial, manufacturing, legal, and public-company costs and the potential need for additional capital.
- Any subsequent changes in leadership, clinical timelines, or material developments after the reporting date.